Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9894345 | Regulatory Peptides | 2005 | 4 Pages |
Abstract
The clinical relevance of the somatostatin receptor subtype 2 (sst2) is well defined in neuroendocrine tumors but it is still a matter of debate whether its expression may have a role also in other tumors not arising from the neuroectoderm. We investigated the prognostic value of the expression levels of sst2 mRNA in a consistent group of patients affected by colorectal cancer. Survival analysis of cancer-related death showed that patients with a high sst2 mRNA expression had an unfavourable outcome (p = 0.037) and a significantly shorter disease-free survival (p = 0.008). Surprisingly, our findings suggest that sst2 gene overexpression is a feature of colorectal tumors that have a negative outlook; in addition, it may allow additional insight into conventional therapeutic approaches for more aggressive tumors, whose prognosis needs to be improved.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Claudia Casini Raggi, Fabio Cianchi, Rosa Valanzano, Michela Cameron Smith, Mario Serio, Mario Maggi, Claudio Orlando,